alemtuzumab

出典: meddic

アレムツズマブ

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2014/01/12 22:55:45」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

英文文献

  • Excellent outcome of matched unrelated donor transplantation in paediatric aplastic anaemia following failure with immunosuppressive therapy: a United Kingdom multicentre retrospective experience.
  • Samarasinghe S, Steward C, Hiwarkar P, Saif MA, Hough R, Webb D, Norton A, Lawson S, Qureshi A, Connor P, Carey P, Skinner R, Vora A, Pelidis M, Gibson B, Stewart G, Keogh S, Goulden N, Bonney D, Stubbs M, Amrolia P, Rao K, Meyer S, Wynn R, Veys P.SourceDepartment of Paediatric & Adolescent Haematology, Great North Children's Hospital, Newcastle upon Tyne, UK.
  • British journal of haematology.Br J Haematol.2012 May;157(3):339-46. doi: 10.1111/j.1365-2141.2012.09066.x. Epub 2012 Feb 29.
  • We retrospectively analysed the outcome of consecutive children with idiopathic severe aplastic anaemia in the United Kingdom who received immunosuppressive therapy (IST) or matched unrelated donor (MUD) haematopoietic stem cell transplantation (HSCT). The 6-month cumulative response rate following
  • PMID 22372373
  • Safety and efficacy of alemtuzumab in the treatment of late acute renal allograft rejection.
  • Upadhyay K, Midgley L, Moudgil A.SourceDepartment of Nephrology, Children's National Medical Center, Washington, DC, USA.
  • Pediatric transplantation.Pediatr Transplant.2012 May;16(3):286-93. doi: 10.1111/j.1399-3046.2011.01615.x. Epub 2011 Nov 24.
  • Upadhyay K, Midgley L, Moudgil A. Safety and efficacy of alemtuzumab in the treatment of late acute renal allograft rejection. Abstract:  Safety and efficacy of alemtuzumab in the treatment of AR in children after renal transplantation is unknown. Five episodes of refractory late AR in three child
  • PMID 22118373

和文文献

  • HLA不適合移植の現状と展望 (特集 血液内科領域の移植医療と再生医療 : 診療と研究における最近の動向)
  • リンパ腫に対する新たな抗体療法の可能性

関連リンク

海外販売名:Campath, MabCampath/一般名:alemtuzumab/治験成分記号:- 対象疾患: B細胞性慢性リンパ性白血病 国内における開発状況: 検討当時の状況:国内では別適応について治験中 治験開始の検討要請中(2007/4 /26 ...
Campath, alemtuzumab is a major step forward in the treatment of B-cell chronic lymphocytic leukemia (B-CLL). ... In clinical trials, the frequency of infusion reactions was highest in the first week of treatment. The following serious ...

関連画像


押しても画像が表示されない場合はサーバが混雑しています。2週間ほどあけて、再度押下してください。



★コメント★

[メモ入力エリア]
※コメント5000文字まで
ニックネーム:
コメント:




表示
個人用ツール


  meddic.jp

リンク
連絡